Zobrazeno 1 - 9
of 9
pro vyhledávání: '"W. J. Hoekstra"'
Autor:
William R. Moore, Lisa Long, Edward P. Garvey, R. J. Schotzinger, W. J. Hoekstra, Mahmoud A. Ghannoum
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:1992-1997
Current therapies used to treat dermatophytoses such as onychomycosis are effective but display room for improvement in efficacy, safety, and convenience of dosing. We report here that the investigational agent VT-1161 displays potent in vitro antifu
Autor:
Wiley A. Schell, Edward P. Garvey, W. J. Hoekstra, A. M. Jones, R. J. Schotzinger, Barbara D. Alexander
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
The in vitro activities of fungal CYP51 inhibitors VT-1161 and VT-1129 were determined for Candida glabrata ( n = 34) and C. krusei ( n = 50). C. glabrata isolates were screened for FKS gene mutations. All isolates were resistant clinically and/or in
Autor:
Edward P. Garvey, William R. Moore, Andrew G. S. Warrilow, Claire M. Hull, R. J. Schotzinger, Diane E. Kelly, Josie E. Parker, Steven L. Kelly, W. J. Hoekstra
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:7121-7127
The binding and cytochrome P45051 (CYP51) inhibition properties of a novel antifungal compound, VT-1161, against purified recombinant Candida albicans CYP51 ( ERG11 ) and Homo sapiens CYP51 were compared with those of clotrimazole, fluconazole, itrac
Autor:
R. J. Schotzinger, Elizabeth A. Lilly, Edward P. Garvey, W. J. Hoekstra, Jack D. Sobel, Paul L. Fidel
Publikováno v:
Antimicrobial agents and chemotherapy. 59(9)
Vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC) remain major health problems for women. VT-1161, a novel fungal CYP51 inhibitor which has potent antifungal activity against fluconazole-sensitive Candida albicans , retained its in vitro potenc
Autor:
W. J. Hoekstra, B. L. Poulter
Publikováno v:
ChemInform. 29
The integrins are cell surface receptors that recognize extracellular matrix adhesive proteins such as fibrinogen, fibronectin, vitronectin, and VCAM-1 (vascular cell adhesion molecule-1). Nonpeptide integrin antagonists designed after the adhesion r
Autor:
D. F. Maccomsey, Bruce E. Maryanoff, W. J. Hoekstra, J. A. Kauffman, M. F. Addo, R. M. Scarborough, B. L. Hulshizer, P. Andrade‐Gordon, D. Oksenberg
Publikováno v:
ChemInform. 29
Autor:
J T, Elliott, W J, Hoekstra, C K, Derian, M F, Addo, B E, Maryanoff, D G, Ahern, G D, Prestwich
Publikováno v:
The journal of peptide research : official journal of the American Peptide Society. 57(6)
Six photoactivatable analogs of the human thrombin receptor activating peptide (TRAP), SFLLRN-NH2, were synthesized by substituting the photoactive amino acid, p-benzoylphenylalanine (Bpa), into each position of the peptide sequence. Platelet aggrega
Autor:
W J, Hoekstra, B L, Poulter
Publikováno v:
Current medicinal chemistry. 5(3)
The integrins are cell surface receptors that recognize extracellular matrix adhesive proteins such as fibrinogen, fibronectin, vitronectin, and VCAM-1 (vascular cell adhesion molecule-1). Nonpeptide integrin antagonists designed after the adhesion r
Autor:
P F, Mulders, W J, Hoekstra, R P, Heybroek, E R, Schapers, A L, Verbeek, G O, Oosterhof, F M, Debruyne
Publikováno v:
European journal of cancer (Oxford, England : 1990). (7)
Patients with T1G3 bladder cancer have a considerable risk for recurrence and/or progressive disease. Until now no consensus has been achieved on the optimal treatment. Within the Dutch South Eastern Bladder Cancer Study Group, 155 patients with a T1